Research Topics
| M E BurczynskiSummaryAffiliation: Wyeth Research Country: USA Publications
| Collaborators
|
Detail Information
Publications
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinomaNatalie C Twine
Discovery Medicine, Wyeth Research, Cambridge, Massachusetts 02140, USA
Cancer Res 63:6069-75. 2003..The present findings have important implications for diagnosis and future clinical pharmacogenomic studies of antitumor therapies...- Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cellsJohn C Rockett
Reproductive Toxicology Division, National Health and Environmental Effects Research Laboratory, Office of Research and Development, United States Environmental Protection Agency, Research Triangle Park, NC 27711, USA
Toxicol Appl Pharmacol 194:189-99. 2004..Also discussed are some of the challenges that must be overcome if the utility of STA is to be proven, and thus permit researchers to move this concept from the laboratory to the clinical environment... - Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinomaMichael E Burczynski
Molecular Profiling and Biomarker Discovery, Wyeth Research, 1 Burtt Road, Andover, MA 01810, USA
Clin Cancer Res 11:1181-9. 2005.... - Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studiesMichael E Burczynski
Wyeth Research, Pharmacogenomic Biomarkers, Biomarker Laboratory, 500 Arcola Road, Collegeville, PA 19426, USA
Pharmacogenomics 7:187-202. 2006..The overall purpose of the review is to focus on the development and application of technologies for the use of peripheral blood cells as a sentinel or surrogate tissue to measure disease state and drug response... - Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cellsElizabeth A DiBlasio-Smith
Department of Biological Technologies, Wyeth Research, 35 CambridgePark Drive, Cambridge, MA 02140, USA
J Transl Med 6:59. 2008..Anti-atherosclerotic effects of synthetic LXR agonists in murine models suggest clinical utility for such compounds... - Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacyM E Burczynski
Clinical Translational Medicine, Wyeth Research, 500 Arcola Road, Collegeville, PA, USA
Toxicol Lett 186:18-21. 2009.... - Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trialsMichael E Burczynski
Discovery Medicine, Wyeth Research, Cambridge, MA 01810, USA
Curr Mol Med 5:83-102. 2005.... - Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cellsMichael E Burczynski
Molecular Profiling and Biomarker Discovery Biomarker Laboratory, Wyeth Research, 500 Arcola Rd, Collegeville PA 19426, USA
J Mol Diagn 8:51-61. 2006..The results suggest that a peripheral blood mononuclear cell-based gene expression signature can provide a molecular biomarker that can complement the standard diagnosis of UC and CD... - Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancerJoseph P Boni
Department of Clinical Pharmacology, Wyeth Research, Collegeville, PA 19426, USA
Clin Pharmacol Ther 77:76-89. 2005..Exposure parameters were also correlated with pharmacogenomic responses in peripheral blood mononuclear cells (PBMCs)... - Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participantsArie Katz
500 Arcola Road, A 3, Collegeville, PA 19426, USA
J Clin Pharmacol 49:643-9. 2009..Central nervous system-related adverse events were observed at the 2 top doses tested. The pharmacodynamic effects described here are the first demonstration of "target engagement" by an LXR agonist in humans... - Use of ex vivo systems for biomarker discoveryEdward R LaVallie
Biological Technologies, Wyeth, Cambridge, MA, USA
Curr Opin Pharmacol 8:647-53. 2008..In this review we discuss the uses of ex vivo systems for both disease tissues and surrogate normal tissues to provide mechanistic insights into drug action and for the purpose of identifying candidate biomarkers... - An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjectsAlbena Patroneva
Department of Neuroscience, Global Medical Affairs, Wyeth Research, Collegeville, PA 19426, USA
Drug Metab Dispos 36:2484-91. 2008..054). Overall, desvenlafaxine had a minimal impact on the PK of desipramine compared with duloxetine, suggesting a lower risk for CYP2D6-mediated drug interactions...